Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
News

New national strategy on prescription drug abuse

Adam Miller
CMAJ May 14, 2013 185 (8) E330; DOI: https://doi.org/10.1503/cmaj.109-4458
Adam Miller
CMAJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

In response to wider concerns about prescription drug abuse, a new national strategy was released Mar. 27 in Ottawa.

Fourteen months in the making, the federally funded Canadian Centre on Substance Abuse (CCSA) released First Do No Harm: Responding to Canada’s Prescription Drug Crisis, a comprehensive report from 46 members of a national advisory council, including pain and addiction specialists, researchers, pharmacists, medical professionals, regulators, law enforcement officials and industry leaders. The strategy focuses on five areas: education, prevention, treatment, enforcement and monitoring of patients and physicians

This report for the first time attempts to define the scope of the prescription drug abuse crisis in Canada and provides a 10-year guideline to reduce the harms associated with prescription drug abuse, by laying out a total of 58 comprehensive, short- and long-term recommendations that the council believes are achievable and will have a collective impact.

“I think a lot of folks have known that there is a problem for some time now, but what is really great about what’s happening here is that the CCSA has taken a leadership role in convening a lot of different stakeholders … to create what really can be viewed as a consensus about how we move forward from here and so my hope is that this is the turning point,” says Dr. Irfan Dhalla, a member of the national advisory council and a physician at St. Michael’s Hospital in Toronto, Ontario.

“There are a lot of recommendations in the strategy and if those recommendations are followed I think we can finally start to bring down the number of overdose deaths and the number of people who become addicted to prescription drugs.”

Figure

A new CCSA report attempts to define the scope of the prescription drug abuse crisis in Canada and provides a 10-year guideline to reduce the harms associated with prescription drug abuse.

Image courtesy of © 2013 Thinkstock

Aglukkaq said during a press conference that prescription drug abuse “represents a serious health and safety issue in Canada” and that the report is a “road map” to guide work over the next decade.

“We must ensure that patients who require appropriate pain management get what they need, at the same time we must continue to promote the safe use of potentially addictive drugs while preventing their misuse and abuse.”

When asked whether her approval of the generic version contradicted the expert advice in the report, Aglukkaq said “[I] make my decisions on the basis of science and the patient needs.”

“There’s lots of comments coming out that maybe we should just ban it, but at the end of the day, again, we have to put the patients first — the patients who require [oxycodone] for legitimate reasons,” she said.

Health Canada itself has been criticized for not taking decisive action on the issue of prescription drug abuse in the past, and for keeping at arm’s length from this new report (www.cmaj.ca/lookup/doi/10.1503/cmaj.109-4379). Doug Spitzig, a pharmacist and member of the national advisory council said that Health Canada was “not even mentioning that [strategy] at all,” which prompted two officials from Health Canada to respond that their department was participating in the strategy but that it was “just not our lead.”

“It is definitely fair to say that Health Canada has not been very active on this file over the last decade, and it’s not just the current health minister,” says Dhalla.

“Hopefully in the next decade we’ll see a very different approach.”

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 185 (8)
CMAJ
Vol. 185, Issue 8
14 May 2013
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
New national strategy on prescription drug abuse
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
New national strategy on prescription drug abuse
Adam Miller
CMAJ May 2013, 185 (8) E330; DOI: 10.1503/cmaj.109-4458

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
New national strategy on prescription drug abuse
Adam Miller
CMAJ May 2013, 185 (8) E330; DOI: 10.1503/cmaj.109-4458
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Saying goodbye to CMAJ News
  • National survey highlights worsening primary care access
  • How Canadian hospitals are decreasing carbon emissions
Show more News

Similar Articles

Collections

  • Topics
    • Canadian government
    • Public health

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire